BridgeBio Pharma, Inc. (BBIO) /
The debt of BridgeBio Pharma, Inc. over the past 9 years
Chart BridgeBio Pharma, Inc.: liquid cash, total debt, net cash, fiscal 2017–2025 Open the chart →At the end of fiscal 2025, the latest fiscal year on file, BridgeBio Pharma, Inc. had liquid cash of $587.48M and total debt of $1.85B: net debt of $1.26B. It had more liquid cash than debt at 3 of the 8 year-ends shown. Total debt was highest at the end of fiscal 2025 ($1.85B) and lowest at the end of fiscal 2018 ($54.51M).
Year by year
| Fiscal year | Liquid cash | Total debt* | Net cash* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $587.48M* | $1.85B | -$1.26B |
| 2024ended Dec 31, 2024 | $681.1M* | $1.72B | -$1.04B |
| 2023ended Dec 31, 2023 | $434.88M* | $1.73B | -$1.29B |
| 2022ended Dec 31, 2022 | $471.92M* | $1.71B | -$1.24B |
| 2021ended Dec 31, 2021 | $836.66M* | $1.7B | -$867.14M |
| 2020ended Dec 31, 2020 | $607.09M* | $477.31M | $129.78M |
| 2019ended Dec 31, 2019 | $545.99M* | $91.79M | $454.2M |
| 2018ended Dec 31, 2018 | $436.09M | $54.51M | $381.58M |
| 2017ended Dec 31, 2017 | — | — | — |
Fiscal years as BridgeBio Pharma, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on BridgeBio Pharma, Inc.
- The revenue of BridgeBio Pharma, Inc.
- The profitability of BridgeBio Pharma, Inc.
- The cash flow of BridgeBio Pharma, Inc.
- All of BridgeBio Pharma, Inc.'s financials, charted
Companies of a similar size
- TXTTextron Inc.
- ARCCAres Capital Corp
- LSCCLATTICE SEMICONDUCTOR CORP
- DOCHealthpeak Properties, Inc.
- MTZMASTEC INC
Not investment advice. This page shows what BridgeBio Pharma, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.